the lilly mdr-tb partnership
DESCRIPTION
The Lilly MDR-TB Partnership. Increasing Corporate Engagement on Tuberculosis Metropolitan Auditorium, Cape Town, 23.02.2010. Creating a sustainable strategy for combating a global public health pandemic. 360° Approach: Partnership Overview. Since 2003, Lilly has lead a comprehensive approach - PowerPoint PPT PresentationTRANSCRIPT
The Lilly MDR-TB PartnershipCreating a sustainable strategy for combating a global public health pandemic
Increasing Corporate Engagement on Tuberculosis
Metropolitan Auditorium, Cape Town, 23.02.2010
2
Since 2003, Lilly has lead a comprehensive approach to fighting MDR-TB through
Awareness and Prevention
Treatment, Training and Surveillance
ResearchTransferring Technology
Community Support and Patient Advocacy
Reaching patients throughout the world
360° Approach: Partnership Overview
3
International Organizations and NGOs– International Federation of Red Cross & Red Crescent Societies – World Health Organization– Foundation for Professional Development– Centers for Disease Control– World Economic Forum– Global Business Coalition– UNICEF– USAID
Government Departments– Department of Health– Department of Public Service and Administration
Healthcare Provider Networks– International Hospital Federation– International Council of Nurses - DENOSA– World Medical Association - SAMA
Manufacturing Partners– Aspen Pharmacare (South Africa)– Hisun (China)– Shasun (India)– SIA/Biocom (Russia)
The Partners
4
World Economic Forum/GBC Develop a Global Awareness Toolkit for
Tuberculosis/MDR-TB in the workplace and disseminate through WEF/GBC member companies
Provide educational material targeting employees and in-plant healthcare staff
Pilot tested in India and adapt for other high-burden countries with large business communities
Conducted 3 workshops in South Africa in 2009 reaching over 60 participants from 33 companies
Workplace Toolkit
5
Transferring of Technology
Share Lilly’s specific and general manufacturing knowledge
Create self-sustaining centers of manufacturing excellence capable of providing additional products and employment
Support reliable generic producers to ensure expanded multi-source availability of the two drugs
Offer manufacturing firms in MDR-TB “hot spots” the technology to produce capreomycin and cycloserine
Give training in GMPs and Good Business Practices
Provide 10 full-time Lilly staff on-site over 4 years for technical assistance/training
Facilities in China and India receive technology to produce capreomycin and cycloserine API’s respectively, and South Africa and Russia produce both products
6
Technology successfully transferred to “hot spot” producers
7
THANK YOU!!!
8
Thank You!
Dr Osborn MahanjanaCorporate Affairs DirectorLilly MDR-TB [email protected] South Africa
www.lilly.comwww.lillymdr-tb.com